One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Coordinating efforts to optimize next-generation kidney replacement therapies: the European Kidney Health Alliance Work Group ‘Breakthrough Innovation’
Fokko Wieringa, Henning Søndergaard, Alberto Ortiz
doi : 10.1093/ckj/sfad016
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 885–890
Chronic kidney disease (CKD) is one of the fastest growing health problems, set to become the fifth global death cause by 2040. Factors contributing to this fast growth include increased survival from other diseases (cancer, cardiovascular disease, diabetes, etc.), population aging, lack of early CKD diagnosis tools, insufficient CKD awareness within healthcare systems, limited therapeutic armamentarium to prevent CKD progression and limitations of currently available kidney replacement therapies (KRTs).
History of creatinine clearance: tribute to a forerunner
Attilio Losito
doi : 10.1093/ckj/sfad024
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 891–895
It is known to few that the path to the discovery of the long-denied plasma creatinine and its clearance was long and difficult. For quite a long time, related controversies between different groups of researchers were widespread and heated.
Glomerular diseases post-hematopoietic stem cell transplantation: pathologic spectrum and plausible mechanisms
Tiffany N Caza, Kenar D Jhaveri
doi : 10.1093/ckj/sfad023
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 896–900
Glomerular disease is an important complication in patients undergoing hematopoietic stem cell transplantation (HSCT), impacting approximately 1%–2% of all HSCT recipients and equating to 700–1400 cases per year worldwide.
Hypertension in young adults with autosomal dominant polycystic kidney disease: a case for early screening?
Melissa A Cadnapaphornchai, Albert C M Ong
doi : 10.1093/ckj/sfad049
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 901–904
ADPKD is the most common hereditary kidney disease and a major cause of kidney failure world-wide. Significant kidney enlargement occurs decades preceding loss of kidney function.
Testing the functional reserve of the kidney before hematopoietic stem cell transplantation: doubt remains
Bart De Moor, Ben Sprangers
doi : 10.1093/ckj/sfad078
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 905–908
Acute kidney injury is a common and important complication following hematopoietic stem cell transplantation. In the nephrology community, acute kidney injury is no longer viewed as a simple temporary and potentially reversible decline in kidney clearance as acute kidney injury imposes a risk for immediate and future complications.
Searching in the maze: sodium–glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival
Laia Oliveras, Núria Montero, Josep M Cruzado
doi : 10.1093/ckj/sfad045
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 909–913
Sodium–glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular and renal outcomes in chronic kidney disease patients with and without diabetes. Kidney transplant recipients have been excluded from landmark trials using SGLT2is and literature on safety and efficacy are scarce.
Interventions to support decision-making, health literacy and self-management in ethnic-minority adults living with chronic kidney disease: a systematic review
Roshana Kanagaratnam, Stephanie Zwi, Angela C Webster, Jennifer Isautier, Kelly Lambert, Heather L Shepherd, Kirsten McCaffery, Kamal Sud, Danielle Marie Muscat
doi : 10.1093/ckj/sfac276
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 914–927
Optimal patient care is directed by clinical practice guidelines, with emphasis on shared decision-making. However, guidelines—and interventions to support their implementation—often do not reflect the needs of ethnic minorities, who experience inequities in chronic kidney disease (CKD) prevalence and outcomes.
Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications
Hans-Joachim Anders, Qiubo Li, Stefanie Steiger
doi : 10.1093/ckj/sfad006
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 928–938
Asymptomatic hyperuricaemia (HU) is considered a pathogenic factor in multiple disease contexts, but a causative role is only proven for the crystalline form of uric acid in gouty arthritis and urate nephropathy.
Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events
Avinash Rao Ullur, Gabrielle Côté, Karyne Pelletier, Abhijat Kitchlu
doi : 10.1093/ckj/sfad014
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 939–951
Immune checkpoint inhibitors (ICI) are now widely used in the treatment of many cancers, and currently represent the standard of care for multiple malignancies. These agents enhance the T cell immune response to target cancer tissues, and have demonstrated considerable benefits for cancer outcomes.
Kidney and blood pressure regulation—latest evidence for molecular mechanisms
Yoko Suzumoto, Laura Zucaro, Anna Iervolino, Giovambattista Capasso
doi : 10.1093/ckj/sfad015
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 952–964
Hypertension is one of the major health problems leading to the development of cardiovascular diseases. Despite a rapid expansion in global hypertension prevalence, molecular mechanisms leading to hypertension are not fully understood largely due to the complexity of pathogenesis involving several factors.
Challenges of defining renal response in ANCA-associated vasculitis: call to action?
Avoiding end-stage kidney disease in patients with anti-neutrophil cytoplasmic antibody–associated vasculitis (AAV) has a high therapeutic priority. Although renal response is a crucial measure to capture clinically relevant changes, clinal trials have used various definitions and no well-studied key surrogate markers to predict renal outcome in AAV exist.
doi : 10.1093/ckj/sfad009
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 965–975
Avoiding end-stage kidney disease in patients with anti-neutrophil cytoplasmic antibody–associated vasculitis (AAV) has a high therapeutic priority. Although renal response is a crucial measure to capture clinically relevant changes, clinal trials have used various definitions and no well-studied key surrogate markers to predict renal outcome in AAV exist.
Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation
Desmond Y H Yap, Davina Lie, Tiffany Lau, Alex Tang, Gavin Chan, Thomas S Y Chan, Joycelyn Sim, Albert K W Lie, Tak Mao Chan
doi : 10.1093/ckj/sfac264
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 976–984
Various glomerular pathologies have been reported in patients who have undergone haematopoietic stem cell transplantation (HSCT), but the data on clinico-pathological correlations and clinical outcome remain limited.
Autosomal dominant polycystic kidney disease in young adults
VÃctor MartÃnez, Mónica Furlano, Laia Sans, Lissett Pulido, Rebeca GarcÃa, MarÃa Vanessa Pérez-Gómez, Jinny Sánchez-RodrÃguez, Miquel Blasco, Cristina Castro-Alonso, Gema Fernández-Fresnedo, Nicolás Roberto Robles, MarÃa Pau Valenzuela, Javier Naranjo, Nadia MartÃn, Melissa Pilco, Irene Agraz-Pamplona, Juan David González-RodrÃguez, Nayara Panizo, Gloria Fraga, Loreto Fernández, MarÃa Teresa López, Cecilia Dall'Anese, Alberto Ortiz, Roser Torra, participants in the REPQRAD
doi : 10.1093/ckj/sfac251
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 985–995
The clinical manifestations of autosomal dominant polycystic kidney disease (ADPKD) usually appear in adulthood, however pediatric series report a high morbidity. The objective of the study was to analyze the clinical characteristics of ADPKD in young adults.
Rationale for the evaluation of renal functional reserve in allogeneic stem cell transplantation candidates: a pilot study
Nicoletta Mancianti, Andrea Guarnieri, Mariapia Lenoci, Francesca Toraldo, Domenica Paola Salvo, Massimo Belluardo, Ernesto Iadanza, Fabio Ferretti, Giuseppe Marotta, Guido Garosi
doi : 10.1093/ckj/sfac268
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 996–1004
The main purpose of our study was to evaluate the ability of renal functional reserve (RFR) to stratify the risk of acute kidney injury (AKI) occurrence within 100 days of hematopoietic stem cell transplantation (HSCT) and to predict any functional recovery or the onset of chronic kidney disease. A secondary aim was to identify the clinical/laboratory risk factors for the occurrence of AKI.
Ex vivo confocal microscopy detects basic patterns of acute and chronic lesions using fresh kidney samples
Jesús Z Villarreal, Javiera Pérez-Anker, Susana Puig, Marc Xipell, Gerard Espinosa, Esther Barnadas, Ana B Larque, J Malvehy, Ricard Cervera, Arturo Pereira, Antonio Martinez-Pozo, Luis F Quintana, Adriana GarcÃa-Herrera
doi : 10.1093/ckj/sfad019
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 1005–1013
Ex vivo confocal microscopy is a real-time technique that provides high-resolution images of fresh, non-fixed tissues, with an optical resolution comparable to conventional pathology. The objective of this study was to investigate the feasibility of using ex vivo confocal microscopy in fusion mode (FuCM) and the haematoxylin and eosin (H&E)-like digital staining that results for the analysis of basic patterns of lesion in nephropathology.
Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view
Natà lia Ramos Terrades, Alicia Senin, Maria A Azancot, Mercedes Gironella, Nestor Toapanta, Sheila Bermejo, Lucia Martin, Fernando Caravaca-Fontán, Clara Cuellar, Joaquin MartÃnez-Lopez, Eva RodrÃguez, Oriol Bestard, Maria Jose Soler
doi : 10.1093/ckj/sfad022
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 1014–1021
Acute kidney injury (AKI) in patients with multiple myeloma (MM) requiring renal replacement treatment (RRT) is associated with high morbidity and mortality. Early reduction of serum free light chains (FLC) using both targeted therapy against MM and intensive hemodialysis (IHD) may improve renal outcomes.
Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study
Ana I Sánchez Fructuoso, Andrea Bedia Raba, Eduardo Banegas Deras, Luis A Vigara Sánchez, RosalÃa Valero San Cecilio, Antonio Franco Esteve, Leonidas Cruzado Vega, Eva Gavela MartÃnez, MarÃa E González Garcia, Pablo Saurdy Coronado, Nancy D Valencia Morales, SofÃa Zarraga Larrondo, Natalia Ridao Cano, Auxiliadora Mazuecos Blanca, Domingo Hernández Marrero, Isabel Beneyto Castello, Javier Paul Ramos, Adriana Sierra Ochoa, Carmen Facundo Molas, Francisco González Roncero, Armando Torres RamÃrez, Secundino Cigarrán Guldris, Isabel Pérez Flores
doi : 10.1093/ckj/sfad007
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 1022–1034
Sodium–glucose cotransporter-2 inhibitors (SGLT2is) have cardioprotective and renoprotective effects. However, experience with SGLT2is in diabetic kidney transplant recipients (DKTRs) is limited.
Prevalence and severity of pruritus in Spanish patients with chronic kidney disease and impact on quality of life: a cross-sectional study
Nuria Aresté, J Emilio Sanchez-Alvarez, Mario Prieto-Velasco, Pablo Molina, Vicent Esteve-Simó, Raquel Ojeda, Juan Manuel Buades, Marian Goicoechea, Rafael Sanchez-Villanueva, Guillermo Alcalde Bezhold, Rosa Elena Pérez-Morales, Ana Blanco Santos, Roser Peiró-Jordan, MarÃa Dolores Arenas, the Pruritus Week Group
doi : 10.1093/ckj/sfac246
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 1035–1037
AA amyloidosis of unknown aetiology: response to treatment with interleukin-1 inhibitors
Ufuk İlgen, İsmail Uçar, Güner Kılıç, Orhan Küçükşahin
doi : 10.1093/ckj/sfad005
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Pages 1038–1042
Correction to: Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
doi : 10.1093/ckj/sfad037
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Page 1043
Correction to: Kidney biopsy in lupus nephritis after achieving clinical renal remission: Paving the way for renal outcome assessment
doi : 10.1093/ckj/sfad038
Clinical Kidney Journal, Volume 16, Issue 6, June 2023, Page 1044
